Every Form 4 that Iovance Biotherapeutics, Inc. (IOVA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow IOVA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IOVA filings page.
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported that Interim CEO & General Counsel Frederick G. Vogt had 15,626 Restricted Stock Units (RSUs) vest on September 8, 2026, converting into an equal number of common shares. Of these, 6,638 shares were withheld by the company to satisfy mandatory tax withholding obligations, which the disclosure states is not an open market sale. Following this RSU vesting event, Vogt continues to hold 93,756 RSUs from the March 5, 2025 grant, which are scheduled to vest in equal quarterly installments.
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported that Chief Operating Officer Igor Bilinsky had restricted stock units vest on September 8, 2026, resulting in the acquisition of 7,813 shares of common stock. These shares came from RSUs converting into common stock at no cash exercise price, with each RSU representing one share. Of the vested shares, 3,976 shares of common stock were withheld by the company at a price of $8.70 per share to satisfy mandatory tax withholding obligations, and this was explicitly stated not to be an open market sale. After this vesting event, 46,878 RSUs from the March 5, 2025 grant remain outstanding and will vest in equal quarterly installments, and no transactions were reported as made under a Rule 10b5-1 trading plan.
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported that Chief Regulatory Officer Raj K. Puri had restricted stock units vest on September 8, 2026, converting 9,766 RSUs into an equal number of common shares. Of these, 4,478 shares were withheld by the company at $8.70 per share to satisfy mandatory tax withholding requirements, which the company notes was not an open-market sale. Following the RSU exercise, 58,599 RSUs from the March 5, 2025 grant remain outstanding and will vest in equal quarterly installments, and no Rule 10b5-1 trading plan is reported.
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported that Interim CEO & General Counsel Frederick G. Vogt had 41,669 restricted stock units (RSUs) vest on September 1, 2026, resulting in the acquisition of an equal number of common shares. Of these, 17,702 shares were withheld by the company at $8.28 per share to satisfy mandatory tax withholding, which the disclosure states was not an open market sale. Following the vesting, 83,338 RSUs from the March 1, 2024 grant remain unvested, in addition to other RSUs he holds.
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported that Chief Regulatory Officer Raj K. Puri had 5,470 Restricted Stock Units (RSUs) vest on September 1, 2026, each converting into one share of common stock. Of these, 2,508 shares of common stock were withheld by the company at $8.28 per share to satisfy mandatory tax withholding requirements, which is explicitly stated not to be an open market sale. Following this vesting event, 10,939 RSUs remain outstanding from the March 1, 2024 grant, in addition to any other RSUs he holds under separate awards.
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported that Chief Operating Officer Igor Bilinsky had 8,789 Restricted Stock Units (RSUs) vest on September 1, 2026, resulting in the issuance of 8,789 shares of common stock. Of these, 4,472 shares of common stock were withheld at $8.28 per share to satisfy mandatory tax withholding, which the company states was not an open market sale. Following the transaction, 17,580 RSUs from the March 1, 2024 grant remain outstanding and will vest in equal quarterly installments; this aggregate RSU figure does not include any other RSUs he holds.
IOVANCE BIOTHERAPEUTICS, INC. reported that Chief Commercial Officer Kirby Daniel Gordon had 10,001 Restricted Stock Units vest and convert into an equal number of common shares on August 10, 2026. Of these, 2,436 shares were delivered or withheld at $6.40 per share to satisfy mandatory tax withholding, which was not an open-market sale. Following the vesting, Gordon held 60,003 RSUs from the February 10, 2025 grant, with the remaining units scheduled to vest in equal quarterly installments.
IOVANCE BIOTHERAPEUTICS, INC. Chief Financial Officer Corleen M. Roche reported the vesting of 49,995 Restricted Stock Units on August 6, 2026, converting into an equal number of common shares. Of these, 21,238 shares were withheld at $6.21 per share to satisfy mandatory tax withholding, leaving 28,757 shares of common stock from this vesting. Following the transaction, she continues to hold 100,005 RSUs from the August 6, 2025 grant, separate from any other RSUs she holds.
WEISER MICHAEL reported acquisition or exercise transactions in this Form 4 filing.
IOVANCE BIOTHERAPEUTICS director Michael Weiser received a grant of 90,316 deferred restricted stock units on June 16, 2026. Each unit represents one share of common stock under the 2018 Equity Incentive Plan. The units vest on the earlier of one year after the grant date or just before the next annual shareholder meeting, and delivery of shares is deferred until specific future events. Following this grant, Weiser holds 90,316 deferred restricted stock units directly.
IOVANCE BIOTHERAPEUTICS director Iain D. Dukes received a grant of 180,632 deferred restricted stock units (DRSUs) linked to the company’s common stock. The award was made at no cash exercise price under the company’s 2018 Equity Incentive Plan.
The DRSUs vest if Dukes continues providing service until the earlier of the first anniversary of the grant date or the day before the next annual shareholder meeting. Actual common shares are issued later, upon specified events such as board departure, a qualifying change in control, or ten years after the grant date.
Countouriotis Athena reported acquisition or exercise transactions in this Form 4 filing.
IOVANCE BIOTHERAPEUTICS, INC. director Athena Countouriotis received a grant of 90,316 deferred restricted stock units (DRSUs) linked to common stock, awarded at no cash cost under the company’s 2018 Equity Incentive Plan.
The DRSUs vest if she continues providing service and will vest on the earlier of the first anniversary of the grant date or the day before the next annual shareholder meeting. Even after vesting, delivery of common shares is deferred until specific events such as board service ending, a qualifying change in control, or ten years after the grant date.
Maynard Ryan D reported acquisition or exercise transactions in this Form 4 filing.
IOVANCE BIOTHERAPEUTICS, INC. director Ryan D. Maynard received a grant of 90,316 deferred restricted stock units, each tied to one share of common stock. The award was made under the company’s 2018 Equity Incentive Plan.
The units vest if he continues providing service until the earlier of the first anniversary of the grant date or the day before the next annual shareholder meeting. Even after vesting, settlement in common stock is deferred until the earlier of three months after he leaves the board or ceases service due to death or disability, a qualifying change in control, or ten years from the grant date.
Puri Raj K. reported acquisition or exercise transactions in this Form 4 filing.
IOVANCE BIOTHERAPEUTICS, INC. granted Chief Regulatory Officer Raj K. Puri 15,000 restricted stock units, each representing one share of common stock. All 15,000 RSUs were reported as directly owned after the award. The grant vests over three years, with one-third vesting on the first anniversary of the grant date and the remaining units vesting in eight equal quarterly installments over the following two years, contingent on continued employment.
IOVANCE BIOTHERAPEUTICS Interim CEO & General Counsel Frederick G. Vogt reported routine equity compensation activity involving restricted stock units (RSUs). On 2026-06-05, RSUs vested and were converted into 15,625 shares of common stock at a stated price of $0.00 per share.
To cover mandatory tax withholding on this vesting, 6,638 shares of common stock were withheld at $4.23 per share. After these transactions, Vogt directly held 562,492 shares of common stock and 109,382 RSUs, with each RSU representing a contingent right to receive one share and the remaining RSUs scheduled to vest in equal quarterly installments.
IOVANCE BIOTHERAPEUTICS, INC. Chief Medical Officer Friedrich Graf Finckenstein reported routine equity compensation activity involving restricted stock units (RSUs). On the transaction date, 7,813 RSUs vested, each converting into one share of common stock. These shares were acquired through an option-style derivative exercise at a stated price of $0.00 per share.
To cover mandatory tax withholding on the vesting, 3,976 common shares were withheld by the company, which the filing clarifies was not an open market sale. After these transactions, the officer directly held 140,111 shares of common stock. The filing also notes 54,691 RSUs remaining from a March 5, 2025 grant, which will vest in equal quarterly installments, providing additional potential future share deliveries as they vest.
IOVANCE BIOTHERAPEUTICS, INC. reports that Chief Regulatory Officer Raj K. Puri had 9,766 restricted stock units vest on June 5, 2026, converting into an equal number of common shares at a $0.00 exercise price.
To satisfy mandatory tax withholding, 3,843 of the newly issued shares were withheld by the company at $4.23 per share; this was not an open-market sale. After these transactions, Puri directly holds 248,114 shares of common stock. RSUs from the same grant are scheduled to continue vesting in equal quarterly installments.
IOVANCE BIOTHERAPEUTICS, INC. Chief Operating Officer Igor Bilinsky reported routine equity compensation activity. On the transaction date, 7,813 restricted stock units (RSUs) vested into shares of common stock, each RSU representing a right to receive one share. To cover mandatory tax withholding on this vesting, 3,976 shares of common stock were withheld by the company; this was explicitly not an open market sale. After these events, Bilinsky directly holds 133,920 shares of common stock and 54,691 RSUs from a March 5, 2025 grant, which are scheduled to vest in equal quarterly installments.
IOVANCE BIOTHERAPEUTICS Interim CEO & General Counsel Frederick G. Vogt had restricted stock units vest into 41,668 shares of common stock on the transaction date. The company withheld 17,701 shares to cover mandatory tax obligations, which was not an open-market sale. Following these transactions, Vogt directly held 553,505 common shares and 125,007 remaining RSUs that will vest in equal quarterly installments.
IOVANCE BIOTHERAPEUTICS Chief Regulatory Officer Raj K. Puri reported routine equity compensation activity. On June 1, 2026, 5,469 restricted stock units (RSUs) vested and converted into the same number of common shares. Of these, 2,508 shares were withheld by the company to cover mandatory tax obligations, which the filing specifies was not an open-market sale. After these transactions, Puri directly holds 242,191 shares of common stock and 16,409 RSUs from the referenced grant, which will continue to vest in equal quarterly installments.
IOVANCE BIOTHERAPEUTICS, INC. Chief Medical Officer Friedrich Graf Finckenstein reported routine equity compensation activity involving restricted stock units (RSUs) and related tax withholding. On the transaction date, RSUs covering 8,790 shares of common stock vested, and an equivalent number of common shares were issued upon conversion of the RSUs.
To cover mandatory tax withholding on this vesting, 4,473 common shares were withheld by the company at a price of $3.96 per share, which the filing notes was not an open market sale. After these transactions, the reporting person directly held 136,274 shares of common stock and 26,369 RSUs, with the remaining RSUs scheduled to vest in equal quarterly installments.
IOVANCE BIOTHERAPEUTICS Chief Operating Officer Igor Bilinsky reported routine equity compensation activity. On the transaction date, 8,790 restricted stock units (RSUs) vested into an equal number of common shares. The company withheld 4,473 shares at $3.96 per share to cover mandatory tax obligations, which was not an open-market sale. Following these transactions, Bilinsky directly held 130,083 shares of common stock and 26,369 RSUs that will continue to vest in equal quarterly installments.
IOVANCE BIOTHERAPEUTICS, INC. Chief Commercial Officer Kirby Daniel Gordon reported routine equity compensation activity. On May 11, 2026, 10,000 restricted stock units (RSUs) vested and converted into common stock, with 2,435 shares withheld by the company to cover mandatory tax obligations rather than sold on the market.
After these transactions, Gordon directly holds 146,946 shares of common stock and 70,004 RSUs, which the filing states will vest in equal quarterly installments. The activity reflects compensation vesting and tax withholding, not open-market buying or selling.
Roche Corleen M. reported acquisition or exercise transactions in this Form 4 filing.
IOVANCE BIOTHERAPEUTICS, INC. reported that its Chief Financial Officer, Corleen M. Roche, received a grant of 132,200 restricted stock units (RSUs) on common stock as equity compensation. Each RSU represents the right to receive one share of common stock if vesting conditions are met.
These RSUs vest over three years, with one-third vesting on the one-year anniversary of the grant date. The remaining RSUs then vest in eight equal quarterly installments over the following two years, provided she remains employed with the company on each vesting date.
Vogt Frederick G reported acquisition or exercise transactions in this Form 4 filing.
IOVANCE BIOTHERAPEUTICS, INC. granted Interim CEO & General Counsel Frederick G. Vogt 235,000 restricted stock units (RSUs) on March 9, 2026. Each RSU represents a contingent right to receive one share of Iovance common stock.
Vesting depends on continued employment. One-third of the RSUs will vest on the one-year anniversary of the grant date. The remaining RSUs will then vest in eight equal quarterly installments over the following two years, starting with the first quarter after the first anniversary.
Puri Raj K. reported acquisition or exercise transactions in this Form 4 filing.
IOVANCE BIOTHERAPEUTICS, INC. granted Chief Regulatory Officer Raj K. Puri 117,500 restricted stock units (RSUs) on common stock. Each RSU represents a right to receive one share if vesting conditions are met. The award vests over three years, with one-third vesting on the first anniversary of grant and the remaining two-thirds vesting in eight equal quarterly installments over the following two years, so long as he remains employed with the company.
GRAF FINCKENSTEIN FRIEDRICH reported acquisition or exercise transactions in this Form 4 filing.
IOVANCE BIOTHERAPEUTICS, INC. reported that its Chief Medical Officer, Friedrich Graf Finckenstein, received a grant of 58,750 restricted stock units. Each RSU represents a contingent right to receive one share of common stock.
The RSUs vest over three years, assuming continued employment. One-third vests on the one-year anniversary of the grant date, and the remaining units vest in eight equal quarterly installments over the following two years. After this grant, the reporting person holds 58,750 RSUs directly.
Kirby Daniel Gordon reported acquisition or exercise transactions in this Form 4 filing.
IOVANCE BIOTHERAPEUTICS, INC. Chief Commercial Officer Daniel Kirby received a grant of 132,200 restricted stock units. Each RSU represents a contingent right to receive one share of common stock. After this grant, he holds 132,200 RSUs.
The RSUs vest over three years if he remains employed. One-third vests on the one-year anniversary of the grant date, and the remaining units vest in eight equal quarterly installments over the following two years.
BILINSKY IGOR reported acquisition or exercise transactions in this Form 4 filing.
Iovance Biotherapeutics reported that Chief Operating Officer Igor Bilinsky received a grant of 117,500 restricted stock units. Each RSU represents one share of common stock. The award vests over three years, with one-third vesting after one year and the balance in eight quarterly installments.
IOVANCE BIOTHERAPEUTICS, INC. interim CEO and General Counsel Frederick G. Vogt reported equity compensation-related transactions. On March 5, 2026, 62,493 restricted stock units (RSUs) vested, converting into 62,493 shares of common stock at a stated price of $0.00 per share.
The company withheld 26,755 common shares at $4.58 per share to cover mandatory tax withholding on the RSU vesting, which is described as not an open market sale. After these transactions, Vogt directly owned 529,538 shares of common stock and 125,007 RSUs from the referenced grant.
IOVANCE BIOTHERAPEUTICS, INC. Chief Medical Officer Friedrich Graf Finckenstein reported equity compensation activity involving restricted stock units (RSUs) and common shares. On March 5, 2026, 31,246 RSUs vested, each converting into one share of common stock at a stated price of $0.00 per share.
Following the RSU vesting and conversion, 16,520 common shares were withheld by the company at $4.58 per share to satisfy mandatory tax withholding requirements, which the disclosure specifies is not an open market sale. After these transactions, Graf Finckenstein directly owned 131,957 shares of common stock and 62,504 RSUs from this grant, with the remaining RSUs scheduled to vest in equal quarterly installments.
IOVANCE BIOTHERAPEUTICS Chief Regulatory Officer Raj K. Puri reported equity compensation activity involving restricted stock units and common stock. On the transaction date, 39,059 restricted stock units vested, each representing a right to receive one share of common stock, and were converted into 39,059 shares of Iovance common stock.
To cover mandatory tax withholding on the vesting, 18,360 shares of common stock were withheld by the company at a price of $4.58 per share. This withholding was not an open market sale of securities. After these transactions, Puri directly held 239,230 shares of common stock and 78,131 restricted stock units, with remaining RSUs scheduled to vest in equal quarterly installments.
IOVANCE BIOTHERAPEUTICS, INC. Chief Operating Officer Igor Bilinsky reported the vesting of 31,246 restricted stock units on March 5, 2026, which were converted into an equal number of common shares at no exercise price.
To cover mandatory tax withholding on this RSU vesting, 16,628 common shares were withheld by the company at a reference price of $4.58 per share, which the disclosure states is not an open market sale. After these transactions, Bilinsky directly held 125,766 common shares and 62,504 RSUs. The remaining RSUs from this March 5, 2025 grant are scheduled to vest in equal quarterly installments, with each unit representing the right to receive one share of common stock.
IOVANCE Biotherapeutics interim CEO and General Counsel Frederick G. Vogt reported vesting of restricted stock units and related tax withholding. On March 2, 2026, RSUs covering 52,087 shares of common stock vested and were delivered at no cost through derivative exercises.
The company then withheld 22,809 common shares at $3.79 per share to cover mandatory tax obligations, which the filing clarifies was not an open market sale of securities. After these transactions, Vogt directly owned 493,800 shares of common stock, with remaining RSUs scheduled to vest in equal quarterly installments.
IOVANCE BIOTHERAPEUTICS, INC. Chief Operating Officer Igor Bilinsky reported equity award activity tied to restricted stock units. On March 2, 2026, RSUs covering 8,790 and 3,517 shares vested and were converted into common stock at no cash exercise price. This resulted in the issuance of 12,307 shares of common stock. Separately, 6,903 shares of common stock were withheld by the company to cover mandatory tax obligations upon vesting, which the filing notes was not an open market sale. After these transactions, Bilinsky directly owned 111,148 shares of common stock.
IOVANCE BIOTHERAPEUTICS, INC. Chief Regulatory Officer Raj K. Puri reported the vesting of 5,470 restricted stock units (RSUs), which converted into an equal number of common shares on March 2, 2026. Each RSU represents a contingent right to receive one share of common stock.
To cover mandatory taxes on this vesting, the issuer withheld 2,798 common shares at $3.79 per share in a tax-withholding disposition that was not an open market sale. Following these transactions, Puri directly held 218,531 shares of common stock and 21,878 RSUs remaining from a March 1, 2024 grant that will vest in equal quarterly installments.
IOVANCE BIOTHERAPEUTICS, INC. Chief Medical Officer Friedrich Graf Finckenstein reported routine equity compensation activity involving restricted stock units (RSUs) and common stock. On the transaction date, RSUs representing 8,790 shares vested, and additional RSUs representing 3,907 shares were also reported, each RSU corresponding to one share of common stock. These conversions resulted in 12,697 shares of common stock, with 7,122 shares of common stock withheld by the company at $3.79 per share to cover mandatory tax obligations, which the filing specifies is not an open market sale. After these transactions, he directly owned 117,231 shares of common stock, along with remaining RSU holdings noted in the filing that will vest in equal quarterly installments.
IOVANCE BIOTHERAPEUTICS, INC. Chief Commercial Officer Daniel Gordon reported the vesting of performance-based restricted stock units after certain financial milestones were achieved. On February 24, 2026, 120,000 shares of common stock vested from previously granted PSUs, while 30,000 related PSUs were cancelled.
To cover mandatory tax withholding on the vesting, 34,165 shares of common stock were withheld by the company at a price of $3.78 per share, which is described as not being an open market sale. After these transactions, Gordon directly holds 139,381 shares of Iovance common stock.
IOVANCE BIOTHERAPEUTICS Chief Commercial Officer Daniel Gordon Kirby reported vesting of restricted stock units and related tax withholding. On February 10, 2026, 39,996 RSUs vested and were converted into the same number of common shares at $0 exercise price.
To cover mandatory taxes on this vesting, 16,450 common shares were withheld by the company at $2.60 per share, which the filing specifies is not an open market sale. After these transactions, Kirby directly holds 53,546 common shares and 80,004 RSUs from the February 10, 2025 grant, with remaining RSUs scheduled to vest in equal quarterly installments.
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported a routine insider equity transaction involving its Chief Regulatory Officer. On 12/01/2025, restricted stock units (RSUs) covering 5,469 shares of common stock vested, and these shares were acquired at an exercise price of $0 as part of the equity award terms.
To cover mandatory tax withholding triggered by the RSU vesting, the company withheld 2,467 shares at a price of $2.23 per share, which was not an open market sale. After this withholding, the officer beneficially owned 215,859 shares of common stock directly. The filing also notes that 27,348 RSUs from the March 1, 2024 grant remain outstanding, scheduled to vest in equal quarterly installments, each RSU representing one share of common stock.